Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01895842

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with low or intermediate-1 risk MDS. The safety of this drug will also be studied, and whether it can help to control the disease.

Status: 
Recruiting
Study Date: 
Sat, 02/01/2014 to Fri, 02/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Ruxolitinib Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle. Starting dose level for Part 2: Maximum tolerated dose from Part 1. Other Names: Jakafi INCB018424 INC424